GET DAILY SIGNALSMacroGenics (MGNX): Can Shares Reach the $7 Analyst Target? (+189% Potential)
Key Takeaways
- The central $7 stock price target used here is the arithmetic mean of three current, individually verified analyst price targets — $11, $6, and $4.
- With shares recently trading near $2.42, reaching $7 would require a gain of roughly 189%, a very large move.
- The analyst target range is unusually wide, from $4 to $11, reflecting sharply divided views on the company's antibody-based cancer pipeline.
- The bullish case rests on ADC (antibody-drug conjugate) programs MGC026 and MGC028 and the lorigerlimab bispecific; the cautious case points to recent clinical safety concerns and a heavy cash burn.
- Key risks include a sharp October 2026 selloff after lorigerlimab safety data, quarterly revenue misses, and the dilution risk common to clinical-stage biotechs.
- B. Riley Securities raised its target to $11 (Buy) in August 2026, Barclays holds a $6 Overweight, and Stifel Nicolaus sits at $4 with a Hold.
Analyst Price Targets and Consensus View
MacroGenics, Inc. (MGNX), a Rockville, Maryland-based clinical-stage biopharmaceutical company, develops antibody-based cancer therapeutics. For this analysis, three current analyst price targets that can be individually attributed to a firm, analyst, and date were reviewed, rather than copying a single website's headline consensus. The targets span approximately $4 to $11, and their arithmetic mean is $7.00, rounded to $7 for the headline.
The dispersion is significant. B. Riley Securities analyst Mayank Mamtani upgraded the stock to Buy in April 2026 and later raised his target from $9 to $11 in August 2026. Barclays' Etzer Darout lifted his target from $4 to $6 in April 2026 and maintained an Overweight rating through late October 2026. Stifel Nicolaus, by contrast, reiterated a Hold with a $4 target in August 2026. Citigroup initiated coverage with a "Positive" rating in October 2026 but did not publish a numeric target, while TD Cowen and H.C. Wainwright hold ratings without current published targets. Weiss Ratings reiterated a sell-equivalent view in early November 2026. The gap between the $11 high and $4 low — nearly triple — captures genuine disagreement about whether the pipeline can translate clinical progress into durable value. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares recently closed near $2.42, toward the lower end of a 52-week range of roughly $1.32 to $5.08, with a market capitalization near $155 million. Reaching the $7 central target would require an advance of about 189%, a very large move by any standard, even for a volatile small-cap biotech. The company reported a quarterly profit of $0.31 per share in August 2026, beating expectations, but revenue of $32.83 million fell well short of the roughly $59 million analysts anticipated — a reminder that collaboration, milestone, and royalty income can be uneven. The stock lost roughly 38% in October 2026 after interim lorigerlimab data raised safety concerns, including severe side effects, underscoring how quickly clinical news can reset sentiment.
What Could Support a Move Toward the Target
The most constructive case centers on the pipeline. MGC026, a B7-H3-targeting ADC, and MGC028, an ADAM9-targeting ADC, give the company exposure to one of oncology's most active drug classes, and positive interim data could justify a significant re-rating. Partnerships with larger firms, including Incyte, Gilead, and Sanofi, provide non-dilutive milestone potential. B. Riley's $11 target and Barclays' $6 Overweight reflect the view that the shares are undervalued relative to the optionality embedded in these programs. A favorable ADC or bispecific readout, new partnership economics, or a capital raise at a higher valuation would all be potential catalysts that could narrow the gap to the $7 level.
What Could Prevent the Target From Being Reached
The principal obstacle is clinical and financial risk. The 2026 lorigerlimab safety data showed high rates of severe side effects, including a reported patient death, and a modest response rate that skeptics argue threatens the drug's competitive viability. Revenue remains lumpy and missed expectations in the latest quarter, while the company continues to burn cash as programs advance, raising the prospect of future equity dilution. Stifel's $4 Hold and the Weiss Ratings sell-equivalent call reflect this caution. Broader pressures — biotech sector rotation, higher-for-longer interest rates that compress valuations for pre-profit companies, and intense competition in ADC and bispecific development — could keep the shares below the target for an extended period.
Technical Levels and Market Structure
The shares trade below both their 50-day and 200-day simple moving averages, near the $3.40–$3.50 zone, which now acts as overhead supply. The 52-week high near $5.08 is the next major resistance level, followed by psychological levels at $6 and the $11 high target. On the downside, the $2.00 area and the 52-week low near $1.32 are key support levels. Because the stock sits well beneath prior highs, any durable move toward $7 would first need to reclaim the moving averages and convert the $5 area from resistance into support.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though the wide $4-to-$11 range shows that individual assumptions differ materially. Investors should watch upcoming clinical updates on MGC026, MGC028, and lorigerlimab, quarterly earnings and revenue recognition, any changes to partnership or milestone economics, cash runway disclosures, and analyst rating and target revisions. Regulatory and competitive developments in the ADC space could also shift sentiment quickly. From what I see, monitoring these catalysts closely remains essential.
AI Daily Buy/Sell Signals
I regularly turn to Tickeron's AI Daily Buy/Sell Signals to track how automated models interpret technical shifts and market conditions across thousands of names. The tool generates Buy, Sell, or Hold signals based on evolving data and can serve as a practical complement when following a name like MGNX. It helps surface potential opportunities or changes in trend without replacing fundamental work, and I find it useful for staying objective amid volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MGNX's RSI Indicator recovers from oversold territory
The RSI Indicator for MGNX moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 23 of the 26 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on November 10, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 228 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 82 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. MGNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.462) is normal, around the industry mean (3.498). P/E Ratio (-10.591) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology
Advertisement